Drugs / H5N1 Influenza Vaccine
H5N1 Influenza Vaccine
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01443663 | Oct 2011 → Sep 2012 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00783926 | Jul 2008 → Feb 2009 | influenza | Alachua Government Services, Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01052402 | Dec 2009 → Nov 2011 | avian influenza | Alachua Government Services, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00517517 | Jul → Sep 2007 | influenza | Alachua Government Services, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00349141 | Jun 2006 → ? | influenza | Alachua Government Services, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00561184 | Oct → Dec 2007 | avian influenza | Novartis Vaccines | Completed | No outcome recorded |
| Phase 2 | NCT00530660 | Sep 2007 → May 2008 | influenza | Alachua Government Services, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01774032 | Mar → Jun 2013 | influenza | Alachua Government Services, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02691130 Background | Nov 2015 → Oct 2016 | influenza | BiondVax Pharmaceuticals ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00537524 Comparator | Sep → Oct 2007 | avian influenza | Novartis Vaccines | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H5N1 influenza vaccine | “Immunogenicity and Safety Study of a 45 Micrograms Dose of Inactivated, Unadjuvanted H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H5N1 and H7N3 Influenza...” NCT01443663 ↗9“A Phase I/II Dose Escalation Study of a Vero Cell-Derived, Whole Virus H5N1 Influenza Vaccine in Healthy Volunteers Aged 18 to 45 Years” NCT00349141 ↗ “Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)” NCT00517517 ↗ |
| Known as | A/Indonesia(H5N1) vaccine | “A subset of participants received a booster immunization with an A/Indonesia(H5N1) vaccine approximately 1 year later.” PMID 24041789 ↗ Sep 2013 |
| Known as | A/Vietnam(H5N1) vaccine | “randomized to receive 2 immunizations with a 7.5-µg or 3.75-µg hemagglutinin (HA) dose of a nonadjuvanted whole-virus A/Vietnam(H5N1) vaccine; adolescents aged 9-17 years...” PMID 24041789 ↗ Sep 2013 |
| Known as | ISIV | “detected by administration of inactivated subvirion influenza A(H5N1) vaccine (ISIV)” PMID 24604819 ↗ Mar 2014 |
| Modality | Vaccine | “we investigated the safety of an H5N1 whole-virus vaccine produced on Vero cell cultures” PMID 18550874 ↗ Jun 2008 |
| Route | Intramuscular | “receive two intramuscular injections” NCT00517517 ↗ |